DEVOS, D., C. MOREAU, M. KYHENG, G. GARCON, A. S. O. ROLLAND, H. BLASCO, P. GELE, T. T. LENGLET, C. VEYRAT-DUREBEX, P. CORCIA, M. DUTHEIL, P. BEDE, A. JEROMIN, P. OECKL, M. OTTO, V. MENINGER, V. DANEL-BRUNAUD, J. C. DEVEDJIAN, J. A. DUCE a P. F. PRADAT. A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Nature Scientific Reports. London: NATURE RESEARCH, 2019, roč. 9, FEB 2019, s. 1-6. ISSN 2045-2322. Dostupné z: https://dx.doi.org/10.1038/s41598-019-39739-5.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis
Autoři DEVOS, D., C. MOREAU, M. KYHENG, G. GARCON, A. S. O. ROLLAND, H. BLASCO, P. GELE, T. T. LENGLET, C. VEYRAT-DUREBEX, P. CORCIA, M. DUTHEIL, P. BEDE, A. JEROMIN, P. OECKL, M. OTTO, V. MENINGER, V. DANEL-BRUNAUD, J. C. DEVEDJIAN, J. A. DUCE a P. F. PRADAT.
Vydání Nature Scientific Reports, London, NATURE RESEARCH, 2019, 2045-2322.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30210 Clinical neurology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.998
Kód RIV RIV/00216224:14110/19:00121482
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1038/s41598-019-39739-5
UT WoS 000459799800067
Klíčová slova anglicky Amyotrophic Lateral Sclerosis; prognostic biomarkers
Štítky Excelence Science, INT, RIV, rivok, user
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 28. 4. 2021 09:29.
Anotace
Accurate patient stratification into prognostic categories and targeting Amyotrophic Lateral Sclerosis (ALS)-associated pathways may pave the way for promising trials. We evaluated blood-based prognostic indicators using an array of pathological markers. Plasma samples were collected as part of a large, phase III clinical trial (Mitotarget/TRO19622) at months 1, 6, 12 and 18. The ALSFRS-r score was used as a proxy of disease progression to assess the predictive value of candidate biological indicators. First, established clinical predictors were evaluated in all 512 patients. Subsequently, pathologic markers, such as proxies of neuronal integrity (Neurofilament light chain and phosphorylated heavy chain), DNA oxidation (8-oxo-2'-desoxyguanosine), lipid peroxidation (4-hydroxy-2-nonenal, isoprostane), inflammation (interleukin-6) and iron status (ferritin, hepcidin, transferrin) were assessed in a subset of 109 patients that represented the whole cohort. Markers of neuronal integrity, DNA and lipid oxidation, as well as iron status at baseline are accurate predictors of disability at 18-month follow-up. The composite scores of these markers in association with established clinical predictors enable the accurate forecasting of functional decline. The identified four biomarkers are all closely associated with 'ferroptosis', a recently discovered form of programmed cell death with promising therapeutic targets. The predictive potential of these pathophysiology-based indicators may offer superior patient stratification for future trials, individualised patient care and resource allocation.
Návaznosti
90090, velká výzkumná infrastrukturaNázev: CZECRIN II
VytisknoutZobrazeno: 29. 7. 2024 00:19